George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Paper in leading Journal

30 Nov 2018 07:00

RNS Number : 9782I
DeepMatter Group PLC
30 November 2018
 

30 November 2018

DeepMatter Group plc

("DeepMatter", or the "Group")

 

Publication of Paper in Science

 

DeepMatter, the AIM-listed company focusing on digitizing chemistry, announces that its founding scientific director, Professor Lee Cronin, and his colleagues at the University of Glasgow have today published a paper in Science, a leading international journal. DeepMatter has rights to intellectual property arising from the laboratory of Professor Cronin as part of its Intellectual Property and Royalty agreement with the University of Glasgow.

 

The paper describes for the first time a method of molecule production which uses downloadable 'blueprints' to easily and reliably synthesise chemicals, such as drug molecules, automatically via a programmable chemical-robot: a 'Chemputer'. The idea of the 'Chemputer' is underpinned by a universal and interoperable standard for writing and sharing chemical recipes, developed by the University of Glasgow team. A number of the scientific concepts detailed in this paper make up a critical part of DeepMatter's commercial strategy.

 

DeepMatter has used its own universal and interoperable standard for writing and sharing chemical recipes as part of its DigitalGlassware™ platform. Currently, the platform allows experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. It is designed to enable scientists to work together effectively, sharing the details of their experiments in real time from anywhere so that work is not needlessly duplicated, time and money wasted, and ultimately so that new discoveries may be made faster.

 

DeepMatter's long term goal is to use DigitalGlassware™ to control robotics and to ultimately progress towards a commercially viable Chemputer™. In 2017, as part of its strategy to build its commercial market presence for the digitization of chemistry, DeepMatter registered the trademark for the Chemputer™ brand.

 

The full scientific Paper, 'Organic synthesis in a modular robotic system driven by a chemical programming language' can be found at www.sciencemag.org

 

Mark Warne, CEO of DeepMatter, commented:

 

"We are very pleased to see the work of our founding scientific director published in Science today. The recognition of such an esteemed publication demonstrates the significance of both the University of Glasgow's important research and our work here at DeepMatter, translating these advances into a commercially viable strategy.

 

"We believe that these developments can truly disrupt the way in which process and discovery chemistry is carried out today, bringing huge financial benefits to those working in these industries. We are very pleased to have the first stage of the DigitalGlasswareTM launch underway and look forward to continuing to educate chemists worldwide as to the benefits of using the platform."

 

For further information:

 

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

 

Stockdale Securities Limited

 

T: 020 7601 6100

Tom Griffiths

Edward Thomas

 

 

 

Alma PR

Caroline Forde

Rebecca Sanders-Hewett

Susie Hudson

 

T: 020 3405 0209

deepmatter@almapr.co.uk

 

About DeepMatter:

 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

 

More information is available here: http://www.deepmattergroup.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAPFNAELPFFF
Date   Source Headline
22nd Mar 201910:39 amRNSHolding(s) in Company
20th Mar 20197:00 amRNSDirectors' Shareholdings
19th Mar 20194:52 pmRNSReplacement - Total Voting Rights and Notice of...
19th Mar 20193:35 pmRNSHolding(s) in Company
19th Mar 20193:32 pmRNSHolding(s) in Company
15th Mar 20198:10 amRNSTotal Voting Rights and Notice of Results
12th Mar 20197:00 amRNSGrant of Options
11th Mar 201912:58 pmRNSResult of Meeting & Directorate Change
7th Mar 20199:00 amRNSIssue of Equity
25th Feb 20197:00 amRNSAcquisition, Placing & Waiver of Rule 9
14th Feb 20193:58 pmRNSHolding(s) in Company
6th Feb 20194:42 pmRNSHolding(s) in Company
6th Feb 20194:41 pmRNSHolding(s) in Company
17th Jan 20197:00 amRNSDisposal of SICM business
20th Dec 20187:00 amRNSUpdate, Conditional Acquisition & Proposed Placing
30th Nov 20187:00 amRNSPublication of Paper in leading Journal
6th Sep 20183:06 pmRNSExercise of Options and Issue of Equity
6th Sep 20187:00 amRNSInterim Results
15th Aug 20187:00 amRNSFurther Pioneer Agreements and Notice of Results
19th Jul 20187:00 amRNSPublication of Scientific Paper
11th Jun 20187:00 amRNSDirectorate Changes
11th Jun 20187:00 amRNSIssue of Equity
16th May 201811:45 amRNSResult of AGM, name change and new website
24th Apr 20187:00 amRNSDirector Dealing
19th Apr 20187:00 amRNSSecond Pioneer Agreement Signed
12th Apr 20187:00 amRNSFirst Pioneer Agreement Signed
5th Apr 20183:28 pmRNSDirector Dealing
28th Mar 20187:00 amRNSFinal results for the year ended 31 December 2017
6th Feb 20187:00 amRNSMoUs signed with pioneers
19th Jan 20189:00 amRNSPublication of Scientific Paper
17th Jan 20187:00 amRNSPublication of Scientific Paper
6th Dec 20177:00 amRNSDirector Dealing
4th Dec 20177:00 amRNSNew Share Option Scheme and Grant to PDMR
1st Dec 20171:01 pmRNSDirectors' Dealing
28th Nov 20179:47 amRNSDirector Dealing
22nd Nov 20175:50 pmRNSHolding(s) in Company
20th Nov 201711:02 amRNSHolding(s) in Company
8th Nov 20178:11 amRNSCompletion of Acquisition, Appointment of Director
3rd Nov 20177:00 amRNSAcquisition of OpenIOLabs Limited
4th Oct 20177:00 amRNSChange of Adviser
12th Sep 20177:00 amRNSHalf-year Report
19th May 201711:34 amRNSResult of AGM
26th Apr 20177:00 amRNSDirectorate Changes
28th Mar 20177:00 amRNSFinal Results
16th Feb 20177:00 amRNSDigital Chemistry to be performed in space
31st Jan 20178:03 amRNSAdvisory Committee
31st Jan 20177:00 amRNSPresentation at Healthcare Conference
9th Jan 20177:00 amRNSDigitalGlasswareT
15th Sep 20167:00 amRNSHalf-year Report
12th May 201611:45 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.